PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations

Emmenegger, Urban; Ko, Yoo‐Joung

doi:10.5489/cuaj.1146

Cited by 11 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The model enabled estimations of important kinetic parameters, such as PSA and CTC production, CTC lifespan, and their respective interindividual variabilities. The estimated PSA half‐life of 85 days was in agreement with literature data . The CTC lifespan was estimated at 58 days; obtaining an experimental estimate of CTC lifespan is difficult, because of the high rate of null counts and the time‐varying production rate, scientific literature on this topic is conflicting …”

Section: Discussionsupporting

confidence: 80%

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration‐Resistant Prostate Cancer

Wilbaux

Tod

Bono

et al. 2015

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

Assessment of treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases. The count of circulating tumor cells (CTCs) is a promising surrogate marker that may replace the widely used prostate-specific antigen (PSA). The purpose of this study was to quantify the dynamic relationships between the longitudinal kinetics of these markers during treatment in patients with mCRPC. Data from 223 patients with mCRPC treated by chemotherapy and/or hormonotherapy were analyzed for up to 6 months of treatment. A semimechanistic model was built, combining the following several pharmacometric advanced features: (1) Kinetic-Pharmacodynamic (K-PD) compartments for treatments (chemotherapy and hormonotherapy); (2) a latent variable linking both marker kinetics; (3) modeling of CTC kinetics with a cell lifespan model; and (4) a negative binomial distribution for the CTC random sampling. Linked with survival, this model would potentially be useful for predicting treatment efficacy during drug development or for therapeutic adjustment in treated patients.

show abstract

Section: Discussionsupporting

confidence: 80%

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration‐Resistant Prostate Cancer

Wilbaux

Tod

Bono

et al. 2015

CPT Pharmacom & Syst Pharma

View full text Add to dashboard Cite

show abstract

“…Indeed, the use of PSA as a biomarker for disease progression is associated with a number of advantageous properties—compared to imaging‐based disease progression markers—as it is easily quantifiable, reproducible, and inexpensive . PSA‐based endpoints, however, are associated with some challenges . First, in some cases, inconsistent relationships between PSA‐derived endpoints and clinical outcome measures have been reported .…”

Section: Prostate Cancermentioning

confidence: 99%

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

Hasselt

Gupta

Hussein

et al. 2015

CPT Pharmacometrics Syst. Pharmacol.

View full text Add to dashboard Cite

Frameworks that associate cancer dynamic disease progression models with parametric survival models for clinical outcome have recently been proposed to support decision making in early clinical development. Here we developed such a disease progression clinical outcome model for castration-resistant prostate cancer (CRPC) using historical phase II data of the anticancer agent eribulin. Disease progression was captured using the dynamics of prostate-specific antigen (PSA). For clinical outcome, overall survival (OS) was used. The model for PSA dynamics comprised parameters for baseline PSA (23.2 ng/ml, relative standard error (RSE) 16.5%), growth rate (0.00879 day−1, RSE 12.6%), drug effect (0.241 µg·h·l−1 day−1, RSE 32.6%), and resistance development (0.0113 day−1, RSE 44.3%). OS was modeled according to a Weibull distribution. Predictors for survival included model-predicted PSA time to nadir (TTN), PSA growth rate, Eastern Cooperative Oncology Group (ECOG) score, and baseline PSA. The developed framework can be considered to support informative design and analysis of drugs developed for CRPC.

show abstract

“…Rising PSA is an indicator of disease progression with the cut-off value as described by prostate cancer working group 3 (PCWG-3) [8]. PSA however fails to show the distribution of disease and changes occurring at each site [18]. It is important to know the volume of disease and the sites of progression for deciding optimal management.…”

Section: Discussionmentioning

confidence: 99%

“…PCa has a unique tropism for bone metastasis which contributes to major disease burden [17]. In most instances, bone metastases are sclerotic or mixed (sclerotic/lytic) in nature, while pure lytic lesions are rare [18]. Most end-stage patients are expected to have multiple bone metastases.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study

Gupta

Choudhury

Rawal

et al. 2018

Nucl Med Mol Imaging

View full text Add to dashboard Cite

The aim of the study was to compare response evaluation criteria in solid tumours 1.1 (RECIST 1.1), positron emission tomography response criteria in solid tumours (PERCIST), European organisation for research and treatment of cancer (EORTC), and MD Anderson (MDA) criteria for response assessment by Gallium 68-prostate-specific membrane antigen positron emission tomography-computed tomography (Ga68-PSMA PET-CT) in metastatic adenocarcinoma prostate cancer (mPCa) patients with biochemical progression. Methods Eighty-eight mPCa patients with pre and post treatment Ga68-PSMA PET-CT were included. A ≥ 25% increase and ≥ 2 ng/ml above the nadir if prostate specific antigen (PSA) drop or ≥ 2 ng/ml above the baseline if PSA does not drop was considered as biochemical progression. RECIST 1.1 and MDA criteria for morphology and PERCIST and EORTC criteria for molecular response were investigated. Percentages of progressive disease (PD), partial response (PR), and stable disease (SD) were calculated. Chi-square test was used for statistical significance.

show abstract

PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations

Cited by 11 publications

References 10 publications

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration‐Resistant Prostate Cancer

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration‐Resistant Prostate Cancer

Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin

Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative Study

Contact Info

Product

Resources

About